

EXHIBIT 7

NEW ENGLAND COMPOUNDING PHARMACY INC. PRODUCTS LIABILITY
LLOYD R. SABERSKI, M.D. on 01/12/2017

DEPOSITION OF

1 IN THE UNITED STATES DISTRICT COURT

2 DISTRICT OF MASSACHUSETTS

3
4 IN RE NEW ENGLAND COMPOUNDING | MDL NO. 02419
5 PHARMACY, INC. PRODUCTS LIABILITY | DOCKET NO.
6 LITIGATION | 1:13-MD-2419-RWZ

7 THIS DOCUMENT RELATES TO:

8 All Actions

9
10 Deposition of LLOYD R. SABERSKI, M.D.

11 Baltimore, Maryland

12 Thursday, January 12, 2017

13 10:00 a.m.

14
15
16
17
18
19
20 Reported by: Angela McKinney, Court Reporter
21
22



DISCOVERY
LITIGATION SERVICES
Court Reporting • Videography • Trial Presentations
Nationwide Coverage

1201 West Peachtree Street
Suite 2300
Atlanta, GA 30309
404.847.0999
www.DiscoveryLit.com

NEW ENGLAND COMPOUNDING PHARMACY INC. PRODUCTS LIABILITY
LLOYD R. SABERSKI, M.D. on 01/12/2017DEPOSITION OF
Pages 2..5

Page 2		Page 4	
1	Deposition of LLOYD R. SABERSKI, M.D., held at	1	C O N T E N T S
2	the offices of:	2	EXAMINATION OF LLOYD R. SABERSKI, M.D. PAGE
3		3	By Mr. Kirby 5
4		4	
5	LAW OFFICES OF PETER G. ANGELOS	5	
6	One Charles Center	6	
7	100 North Charles Street	7	
8	Baltimore, Maryland 21201	8	E X H I B I T S
9	(410) 649-2000	9	(Attached)
10		10	DEPOSITION EXHIBIT PAGE
11		11	Ex. 1611-1 Amended deposition notice 8
12		12	Ex. 1611-2 Dr. Saberski's billing 8
13	Pursuant to agreement, before Angela McKinney,	13	Ex. 1611-3 Expert report 9
14	Professional Court Reporter and Notary Public of the	14	Ex. 1611-4 CV 10
15	state of Maryland.	15	Ex. 1611-5 Deposition list 39
16		16	Ex. 1611-6 Trial list 39
17		17	Ex. 1611-7 Fee schedule 46
18		18	Ex. 1611-8 DHMH press release 206
19		19	
20		20	
21		21	
22		22	

Page 3		Page 5	
1	A P P E A R A N C E S	1	P R O C E E D I N G S
2	ON BEHALF OF THE PLAINTIFFS:	2	LLOYD R. SABERSKI, M.D., having been
3	JAY D. MILLER, ESQUIRE	3	previously sworn, testified as follows:
4	LAW OFFICES OF PETER G. ANGELOS	4	EXAMINATION
5	One Charles Center	5	BY MR. KIRBY:
6	100 North Charles Street	6	Q Good morning, Dr. Saberski. I introduced
7	Baltimore, Maryland 21201	7	myself off the record. But for the record, my name is
8	(410) 649-2000	8	Greg Kirby and this is Catherine Steiner and we
9	MICHAEL COREN, ESQUIRE	9	represent the Box Hill defendants in this case. I know
10	COHEN, PLACETELLA & ROTH, P.C.	10	you have been deposed many times before and related to
11	127 Maple Avenue	11	other plaintiffs in these cases, but just to explain so
12	Red Bank, New Jersey 07701	12	that we're all on the same page --
13	(723) 747-9003	13	A Yeah, go ahead.
14	ON BEHALF OF THE DEFENDANTS:	14	Q This is my only opportunity to ask you
15	GREGORY K. KIRBY, ESQUIRE	15	questions. Let me just wait for you to finish.
16	CATHERINE W. STEINER, ESQUIRE	16	A I'm just missing my notebook. I apologize.
17	PESSIN KATZ LAW, P.A.	17	Q This is my only opportunity to ask you
18	901 Dulaney Valley Road	18	questions and find out what your answers are to those
19	Suite 500	19	questions. You are under oath. If I ask you a
20	Towson, Maryland 21204	20	question and you don't understand it, will you ask me
21	(410) 938-8800	21	to repeat it or rephrase it?
22		22	A Yes, sir.



DISCOVERY
LITIGATION SERVICES
Court Reporting • Videography • Trial Presentations
Nationwide Coverage

1201 West Peachtree Street
Suite 2300
Atlanta, GA 30309
404.847.0999
www.DiscoveryLit.com

NEW ENGLAND COMPOUNDING PHARMACY INC. PRODUCTS LIABILITY
LLOYD R. SABERSKI, M.D. on 01/12/2017

DEPOSITION OF
Pages 62..65

<p style="text-align: right;">Page 62</p> <p>1 A I don't know how they come up with the</p> <p>2 ratings, but it sounds appropriate that Yale is on the</p> <p>3 list.</p> <p>4 BY MR. KIRBY:</p> <p>5 Q They are reputable institutions?</p> <p>6 A Those are hospitals.</p> <p>7 Q Would it surprise you if all of them were on</p> <p>8 the customer list that we looked at on 1585-12.</p> <p>9 MR. COREN: Objection to form.</p> <p>10 A Doesn't surprise me one bit. They are on a</p> <p>11 customer list.</p> <p>12 BY MR. KIRBY:</p> <p>13 Q Have you ever done business with NECC?</p> <p>14 A Business?</p> <p>15 Q Have you ever had any interaction whatsoever</p> <p>16 with the New England Compounding Center?</p> <p>17 A Yes.</p> <p>18 Q Describe that.</p> <p>19 A A sales rep came to my office in the early</p> <p>20 2000s suggesting that we purchase compounded steroids</p> <p>21 from them. His marketing pitch was it was preservative</p> <p>22 free and it was cheaper. And I engaged him in a</p>	<p style="text-align: right;">Page 64</p> <p>1 something improper?</p> <p>2 A I really didn't understand the gravity of</p> <p>3 what I was saying no to. I think if I had to do it all</p> <p>4 over again, I certainly would have called up the</p> <p>5 appropriate authority. Clearly they were in the wrong</p> <p>6 and we at my office knew that it was wrong.</p> <p>7 Q Can we agree that NECC caused the</p> <p>8 contamination of the MPA?</p> <p>9 A Yes.</p> <p>10 Q We can agree that Dr. Bhambhani didn't cause</p> <p>11 the contamination?</p> <p>12 A No.</p> <p>13 MS. STEINER: Yes, you can agree that, no,</p> <p>14 she did not?</p> <p>15 A Yes.</p> <p>16 BY MR. KIRBY:</p> <p>17 Q Sorry. I thought we were having a moment.</p> <p>18 I understood.</p> <p>19 MS. STEINER: Just clarify that.</p> <p>20 BY MR. KIRBY:</p> <p>21 Q So we can agree that Dr. Bhambhani did not</p> <p>22 cause the contamination, right?</p>
<p style="text-align: right;">Page 63</p> <p>1 conversation as to why I would want to do that, given</p> <p>2 there are commercially-available products that are</p> <p>3 perfectly fine.</p> <p>4 Q Did you ask him why they were selling -- did</p> <p>5 you ask him why they were selling preservative-free</p> <p>6 products as a compounder if there were other</p> <p>7 commercially-available products available?</p> <p>8 A I did either directly or indirectly, but he</p> <p>9 was a salesperson who knew nothing. Essentially my</p> <p>10 office would have nothing to do with NECC because they</p> <p>11 were offering a product that was readily available.</p> <p>12 Q So in your estimation, that was improper to</p> <p>13 do, correct?</p> <p>14 A Yes.</p> <p>15 Q And did you ever report NECC to the</p> <p>16 Connecticut Board of Pharmacy?</p> <p>17 A I did not.</p> <p>18 Q Or the Massachusetts Board of Pharmacy or</p> <p>19 the FDA?</p> <p>20 A I did not.</p> <p>21 Q No one. Okay. Is there a reason why you</p> <p>22 didn't report them if you thought they were doing</p>	<p style="text-align: right;">Page 65</p> <p>1 A Yes, we can agree.</p> <p>2 Q Can we agree that NECC had a duty to its</p> <p>3 customers to provide safe products?</p> <p>4 A Yes.</p> <p>5 Q They had a duty to provide -- strike that.</p> <p>6 That they had a duty to accurately represent</p> <p>7 the safety and quality of its products to customers and</p> <p>8 potential customers?</p> <p>9 A Yes.</p> <p>10 Q Can we agree that in the summer and fall of</p> <p>11 2012 that NECC failed in its duty to do all those</p> <p>12 things that we just discussed?</p> <p>13 A I believe so.</p> <p>14 Q Do you believe that NECC violated the law in</p> <p>15 these cases?</p> <p>16 MR. COREN: Objection to form.</p> <p>17 A I'm not a lawyer. However, I believe they</p> <p>18 did.</p> <p>19 BY MR. KIRBY:</p> <p>20 Q I think I know your answer, but just to be</p> <p>21 clear, when you say you think they did, do you have any</p> <p>22 statutes or laws or regulations in mind from --</p>



DISCOVERY
LITIGATION SERVICES
Court Reporting • Videography • Trial Presentations
Nationwide Coverage

1201 West Peachtree Street
Suite 2300
Atlanta, GA 30309
404.847.0999
www.DiscoveryLit.com

NEW ENGLAND COMPOUNDING PHARMACY INC. PRODUCTS LIABILITY
LLOYD R. SABERSKI, M.D. on 01/12/2017

DEPOSITION OF
Pages 66..69

<p style="text-align: right;">Page 66</p> <p>1 A Yes. I wrote it down this morning just so</p> <p>2 that I'd get it right. The Federal Food, Drug and</p> <p>3 Cosmetic Act of 1938.</p> <p>4 Q Anything else?</p> <p>5 A Well, over the years that law evolved and</p> <p>6 had a number of different codifiers. It was adjusted</p> <p>7 over the years, but that was the principal law that was</p> <p>8 put into place.</p> <p>9 Q When did you look up the Federal Food, Drug</p> <p>10 and Cosmetic Act of 1938?</p> <p>11 A A couple years ago.</p> <p>12 Q Do you know specifically what you would say</p> <p>13 they violated with regards to that Federal Food, Drug</p> <p>14 and Cosmetic Act?</p> <p>15 A Almost everything involving compliance.</p> <p>16 Q Can we agree that NECC's conduct in these</p> <p>17 cases caused injury to the patients?</p> <p>18 A Well, I think their conduct in conjunction</p> <p>19 with the misconduct of the physicians caused injury to</p> <p>20 patients.</p> <p>21 Q Fair enough. At least in part we can</p> <p>22 agree --</p>	<p style="text-align: right;">Page 68</p> <p>1 BY MR. KIRBY:</p> <p>2 Q Do you agree that if proper testing had been</p> <p>3 done, it likely would have detected the contamination?</p> <p>4 MR. MILLER: Object to form.</p> <p>5 A I think you need to speak to somebody who</p> <p>6 does the testing.</p> <p>7 BY MR. KIRBY:</p> <p>8 Q Do you agree that because NECC was licensed</p> <p>9 as a pharmacy in the state of Massachusetts that the</p> <p>10 Massachusetts Board of Pharmacy had the power and</p> <p>11 authority to regulate NECC?</p> <p>12 MR. MILLER: Objection to form.</p> <p>13 A Again, that's a legal question. I don't</p> <p>14 really know the distinction between the federal</p> <p>15 government and the state government in terms of that</p> <p>16 particular question.</p> <p>17 BY MR. KIRBY:</p> <p>18 Q Do you agree that the Massachusetts Board of</p> <p>19 Pharmacy was responsible for enforcing the laws with</p> <p>20 respect to compounding pharmacies within its borders?</p> <p>21 A Again, that's a legal question. I'm a</p> <p>22 physician. My guess is you would think that's the</p>
<p style="text-align: right;">Page 67</p> <p>1 A In part, yes.</p> <p>2 Q You are not going to defend any of NECC's</p> <p>3 actions in these cases?</p> <p>4 A No. But if these products were never</p> <p>5 ordered or never administered, these patients would not</p> <p>6 have a problem.</p> <p>7 Q The standard of care did not require</p> <p>8 Dr. Bhambhani to travel to Boston to NECC's facility to</p> <p>9 inspect them, did it?</p> <p>10 A No.</p> <p>11 Q Have you ever heard a reference to UniClean</p> <p>12 in this litigation?</p> <p>13 A No.</p> <p>14 Q Are you familiar with ARL's role in testing</p> <p>15 the NECC's MPA product here?</p> <p>16 A That's a name I've seen and I know they have</p> <p>17 been involved in testing, but I really don't know much.</p> <p>18 Q Do you believe that whoever tested the</p> <p>19 product for NECC fell below the standard in terms of</p> <p>20 its testing?</p> <p>21 MR. MILLER: Objection to form.</p> <p>22 A No, I'm not an expert in testing.</p>	<p style="text-align: right;">Page 69</p> <p>1 case, but it's a legal question. I can't answer that.</p> <p>2 Q I think you answered a similar question in</p> <p>3 your other Maryland state deposition.</p> <p>4 Would it be the Massachusetts Board of</p> <p>5 Pharmacy's responsibility to ensure that a compounding</p> <p>6 pharmacy obtains an individual prescription for its</p> <p>7 drugs?</p> <p>8 MR. MILLER: Objection to form.</p> <p>9 A Again, I don't know whose responsibility it</p> <p>10 would be in terms of that.</p> <p>11 BY MR. KIRBY:</p> <p>12 Q I think you answered affirmatively in your</p> <p>13 state deposition. If that was the case, would you have</p> <p>14 any reason to change that opinion now?</p> <p>15 A Well, I'm not sure what the basis of my</p> <p>16 opinion was at that time because I really don't know</p> <p>17 the law, that aspect of the law.</p> <p>18 Q Would you agree as a general concept that</p> <p>19 it's reasonable for a health care provider in a state</p> <p>20 to assume that that state regulatory board is actually</p> <p>21 regulating the licensee that it's responsible for?</p> <p>22 MR. MILLER: Objection to form.</p>



DISCOVERY
LITIGATION SERVICES
Court Reporting • Videography • Trial Presentations

Nationwide Coverage

1201 West Peachtree Street
Suite 2300
Atlanta, GA 30309
404.847.0999
www.DiscoveryLit.com

NEW ENGLAND COMPOUNDING PHARMACY INC. PRODUCTS LIABILITY
LLOYD R. SABERSKI, M.D. on 01/12/2017

DEPOSITION OF
Pages 166..169

<p style="text-align: right;">Page 166</p> <p>1 Massachusetts Board of Pharmacy had information that</p> <p>2 that's the way that NECC was conducting business that</p> <p>3 that would be inappropriate, correct?</p> <p>4 A Yes.</p> <p>5 Q But they didn't stop NECC from selling</p> <p>6 drugs, did they, until the outbreak?</p> <p>7 MR. COREN: Objection as to the form.</p> <p>8 A Well, they did at the outbreak.</p> <p>9 BY MR. KIRBY:</p> <p>10 Q Prior to the outbreak, they didn't stop</p> <p>11 them?</p> <p>12 A In 2002 I think they were trying to.</p> <p>13 Q They didn't prevent NECC from continuing to</p> <p>14 sell their drugs all across the country, right? Or at</p> <p>15 least in Maryland? We'll go with that.</p> <p>16 A I don't know whose jurisdiction it was for</p> <p>17 that kind of step, but that's not really my area of</p> <p>18 expertise.</p> <p>19 Q Probably should have been one or the other</p> <p>20 at least, right?</p> <p>21 A Right.</p> <p>22 Q Maybe even both?</p>	<p style="text-align: right;">Page 168</p> <p>1 BY MR. KIRBY:</p> <p>2 Q Even if she had done it that way, she still</p> <p>3 would have gotten back contaminated drugs?</p> <p>4 A I think that's basically correct, but there</p> <p>5 is a small caveat here, and we kind of pounded this to</p> <p>6 the ground earlier, that she was getting multidose</p> <p>7 vials without a preservative and by getting shipped a</p> <p>8 multidose vial without preservative, by accessing it</p> <p>9 multiple times, if that vial happened to be bad, she's</p> <p>10 potentially vectoring bad stuff to multiple people.</p> <p>11 Q But specific to the prescription issue, that</p> <p>12 in and of itself didn't have an effect? Didn't change</p> <p>13 the outcome?</p> <p>14 MR. COREN: Objection as to the form.</p> <p>15 A Probably not. I could probably draw some --</p> <p>16 we'll just say that.</p> <p>17 BY MR. KIRBY:</p> <p>18 Q Would you agree that Dr. Bhambhani was</p> <p>19 essentially ordering NECC's MPA and other drugs I guess</p> <p>20 for office use?</p> <p>21 A Well, I don't know what her facility is.</p> <p>22 Isn't it a surgery center?</p>
<p style="text-align: right;">Page 167</p> <p>1 MR. COREN: Objection as to form.</p> <p>2 BY MR. KIRBY:</p> <p>3 Q And you are not aware, and if you are, just</p> <p>4 provide me the information, that anyone at the Maryland</p> <p>5 Board of Physicians, the Board of Pharmacy, the</p> <p>6 Massachusetts Board of Pharmacy, the FDA, the CDC, the</p> <p>7 DEA, et cetera, ever told Dr. Bhambhani or anyone that</p> <p>8 they were ordering the drugs wrong and that they</p> <p>9 couldn't do it that way? You don't have any evidence</p> <p>10 of that, do you?</p> <p>11 A Two questions. I have no evidence and I'm</p> <p>12 not aware of anybody telling her that.</p> <p>13 Q Can we at least agree -- so I understand</p> <p>14 your position, then, that she was violating standards</p> <p>15 because she should have used patient-specific</p> <p>16 prescriptions or whatever. Okay. Let's assume that</p> <p>17 she had a need to use a compounding pharmacy, a</p> <p>18 justifiable need to use a compounding pharmacy, and</p> <p>19 that she was submitting individual patient</p> <p>20 prescriptions. We can at least agree that that had no</p> <p>21 effect on the patient injuries, correct?</p> <p>22 MR. COREN: Objection as to the form.</p>	<p style="text-align: right;">Page 169</p> <p>1 Q An ambulatory surgery center.</p> <p>2 A I think you have to be careful about how you</p> <p>3 use your words. A surgery center is different than an</p> <p>4 office. She may very well have been using them in</p> <p>5 both, but I'm aware of the surgery center stuff.</p> <p>6 Q Pardon my incorrect grammar, but when I said</p> <p>7 office, I was suggesting the surgery center.</p> <p>8 A Okay.</p> <p>9 Q And if she had ordered from an FDA</p> <p>10 manufacturer, she wouldn't have needed a prescription,</p> <p>11 right?</p> <p>12 A Right. FDA manufacturers, you are allowed</p> <p>13 to order a stock.</p> <p>14 Q That's essentially what Dr. Bhambhani was</p> <p>15 doing here, correct?</p> <p>16 A Right, which was against the law.</p> <p>17 Q I may have asked this before and I can't</p> <p>18 remember so I'll ask it this time. We can agree the</p> <p>19 drugs, the MPA that she's ordering is never going in</p> <p>20 the patient's hands, right? It's always going to be</p> <p>21 just used by and administered by a skilled professional</p> <p>22 like Dr. Bhambhani, correct?</p>



DISCOVERY
LITIGATION SERVICES
Court Reporting • Videography • Trial Presentations
Nationwide Coverage

1201 West Peachtree Street
Suite 2300
Atlanta, GA 30309
404.847.0999
www.DiscoveryLit.com